505(b)(2) Pathway
Integrated Strategies for a Faster Path to Approval
Premier Research is a global CRO with unrivalled experience guiding sponsors through the US 505(b)(2) development pathway, from early regulatory strategy and FDA engagement through clinical pharmacology, nonclinical planning, CMC, clinical development, and NDA submission.
3,500+
Unique drug products evaluated
75+
Interactions with the FDA each year
50+
PhDs on staff with broad multidisciplinary expertise
20+
Years’ experience supporting 505(b)(2) development
505(b)(2) CRO Services and Development Capabilities
Regulatory Strategy and FDA Engagement
Guidance to help sponsors determine whether the 505(b)(2) pathway is appropriate, identify reference products, define data reliance strategies, and prepare for productive FDA interactions.
Learn MoreClinical Pharmacology, PK Bridging, and MIDD
Evaluation of existing data and design of 505(b)(2) bridging studies, pharmacokinetic, and model-informed drug development (MIDD) strategies that reduce the number of studies needed and support a scientifically robust and regulatory-aligned bridge to an approved reference product.
Learn MoreNonclinical Strategy and Toxicology
Identifying where existing data may be leveraged in lieu of sponsor studies, where new studies are needed to open an IND or for NDA submission, and how to justify an efficient nonclinical program to FDA, applying scientifically sound, appropriately aggressive strategies.
Learn MoreChemistry, Manufacturing, and Controls
Aligning CMC planning with the accelerated pace of 505(b)(2) development while addressing product quality, manufacturing robustness, reproducibility, and approval readiness.
Learn MoreStrategic Guidance for Navigating 505(b)(2) Complexity
The 505(b)(2) pathway can offer sponsors a powerful opportunity to streamline development, reduce clinical burden, and bring differentiated products to market faster. But taking advantage of this pathway requires nuanced expertise. Each program requires a tailored strategy that connects existing data, regulatory precedent, product-specific evidence, and FDA expectations. Premier Research brings a depth of experience to help sponsors avoid conducting any more studies than they need. Our teams understand the history, precedents, pitfalls, and practical workarounds that can make the difference between an efficient development pathway and conducting studies that are not needed.
505(b)(2) Development
Meet the Experts
Angela Drew, Ph.D.
Vice President, Regulatory Strategy
Angela Drew, PhD, has been a regulatory strategist since 2011. During this time, she has prepared regulatory submissions, conducted FDA meetings to obtain feedback on development programs, and advised clients on developing products for submission via the 505(b)(2) regulatory pathway. Prior to joining the pharmaceutical industry as part of the Premier team, Angela held academic appointments at the University of Cincinnati and Melbourne University investigating the interactions between inflammation, coagulation, and cancer metastasis.
Learn more
Stacey Ayres, Ph.D.
Vice President, Regulatory Strategy
Stacey A. Ayres, PhD, is an accomplished regulatory strategist with more than two decades of pharmaceutical industry experience and nearly two decades specializing in the 505(b)(2) drug approval pathway. As Vice President, Regulatory Strategy, Dr. Ayres leads regulatory strategy for complex drug development programs across a broad range of therapeutic areas, including small molecules, biologics, and drug-device combination products. Dr. Ayres has extensive experience defining scientifically sound, streamlined pathways to regulatory approval, integrating clinical, nonclinical, chemistry, manufacturing, and controls (CMC), device, and regulatory considerations to address complex development challenges and manage regulatory risk. Her approach emphasizes pragmatic strategies that improve development efficiency, leverage existing knowledge and regulatory precedent, and support meaningful product differentiation. She has extensive experience engaging with FDA on 505(b)(2) and other complex drug development programs, including numerous pre-IND, End-of-Phase 2, pre-NDA, and other regulatory interactions. A particular area of expertise is developing creative and pragmatic 505(b)(2) strategies that leverage existing information, regulatory precedent, scientific bridging, and appropriate reliance pathways to define efficient development programs and the evidence necessary to support approval. Her experience also encompasses INDs, NDAs, and ANDAs, as well as the development of regulatory positions, briefing packages, and scientific justifications supporting FDA interactions throughout the product lifecycle. Dr. Ayres also has extensive experience developing strategies to leverage regulatory designations, incentives, and exclusivity opportunities, including Orphan Drug Designation, Qualified Infectious Disease Product designation, Fast Track and Breakthrough Therapy Designations, Rare Pediatric Disease Designation, and priority review voucher programs. Her experience includes orphan drug strategies involving clinical superiority, major contribution to patient care, and orphan subsets, as well as Citizen Petitions and Suitability Petitions. Complementing her regulatory strategy work, Dr. Ayres has experience in product ideation, product selection, portfolio strategy, and integrated feasibility assessment for 505(b)(2) opportunities. She integrates scientific, medical, regulatory, development, and commercial considerations to assess product viability and identify efficient development strategies, with a focus on managing regulatory risk, leveraging available regulatory opportunities, and supporting commercial differentiation.
Learn more
Ken Phelps
Strategic Advisor, Consulting
In 2003, Ken Phelps applied more than three decades of industry experience to found Camargo Pharmaceutical Services in Cincinnati with Dr. Ruth Stevens (chief scientific officer and executive vice president). It is no coincidence that 2003 was also the year the US FDA introduced guidelines governing the 505(b)(2) approval pathway. In the beginning, Camargo focused solely on being the industry’s 505(b)(2) development partner of choice. Today, Camargo has become part of Premier Consulting, which has led the largest percentage of 505(b)(2) submissions of any team submitting to the FDA—Premier Consulting has led more than 1100 agency meetings and is the industry authority in 505(b)(2). Before founding Camargo, Phelps’ diverse background in drug development had led to a number of executive-level assignments in the areas of quality control, project management and regulatory, clinical and medical affairs at Duramed Pharmaceuticals. Phelps also held a number of positions at Merrell-National Labs (which merged to become Merrell Dow and later evolved into Aventis), where he was responsible for global quality assurance, quality control, and processing technology, with an assignment based in Milan, Italy. Today, as a thought leader in the shifting landscape of drug development and emergent pathways around the globe, Phelps addresses the financial challenges of pharmaceutical companies caused by the generics cliff and routinely presents on the topic at events worldwide. He has recently been invited to speak on the topic at DCAT and other international conferences and on how companies can realize the opportunities of 505(b)(2) and expanded marketability. Phelps is also a founding member of the 505(b)(2) Forum, an assembly of product developers and service providers interested in improving best practices across the 505(b)(2) development process. He publishes articles frequently and is a featured interviewee in publications, videos and podcasts concerning new, repositioned, and differentiated product development around the globe.
Learn more
William Salminen, Ph.D., DABT, PMP
Vice President, Toxicology and Clinical Pharmacology/Pharmacometrics
Dr. Salminen has over 20 years of drug development experience for an array of drug products and indications. He is board-certified in toxicology (DABT) and project management (PMP) and a subject matter expert in nonclinical safety and toxicology support for drug product development. His experience includes regulatory strategy and advice, nonclinical safety and toxicology strategy and advice, US FDA pre-Investigational New Drug (pre-IND) meetings, IND applications and maintenance, and New Drug Application (NDA) and Biologics License Application (BLA) submissions. Dr. Salminen has significant experience with 505(b)(2) NDAs and the unique regulatory, nonclinical, and clinical strategies involved with developing drugs under this pathway. He also has FDA-applied research experience with developing new biomarkers of drug-induced liver injury.
Learn more
Agnieszka Marcinowicz, Ph.D.
Director, Clinical Pharmacology
Agnieszka Marcinowicz, Director, Clinical Pharmacology, has a Ph.D. in Physical Chemistry with experience in drug development, bioanalysis, preclinical studies, clinical development, data analysis, pharmacokinetics and pharmacodynamics and clinical pharmacology. Dr. Marcinowicz leverages her expertise in PK analysis and modeling, statistical analysis, bioanalysis, and nonclinical and clinical drug development to determine and implement unique MIDD approaches for a range of drugs, indications, and routes of administration. Dr. Marcinowicz also works closely with Premier’s regulatory experts to write and submit PK reports and clinical study protocols and reports.
Learn more
Seth DePuy, Ph.D.
Sr. Director, Regulatory & Product Strategy
Dr. Seth DePuy is a scientist and mentor with over 10 years of research experience in both academia and industry and over 5 years of experience in drug development and regulatory affairs for a broad range of therapeutic areas and unique drug products and/or dosage forms. Dr. DePuy is accomplished in performing thorough background research and assessing scientific and regulatory information to develop/support regulatory strategy and produce quality on-time deliverables to all stakeholders. Dr. DePuy’s key experience includes (but is not limited to) regulatory strategy and support of US FDA meetings, IND applications and maintenance, expedited programs and designation applications, and NDA submissions. He possesses significant expertise in 505(b)(2) drug development and the unique strategies required for this development pathway.
Learn more
Catherine Gatza, Ph.D.
Vice President, Regulatory Strategy
Catherine Gatza, Ph.D., is an experienced regulatory strategist with over 12 years of experience in both consulting and the Sponsor side of the pharmaceutical industry. Dr. Gatza is skilled in the development of strategic and streamlined drug development programs across multiple therapeutic areas, with a specialization in 505(b)(2) applications. She has led the development of regulatory strategy for small, mid-,and large pharmaceutical companies, from early-stage proof-of-concept to NDA submissions and approvals, as well as post-approval support for small molecules, biologics, fixed dose combination, and drug-device combination products. She is experienced in preparation, oversight, and review of regulatory documentation for client and FDA submissions including feasibility and strategic assessments, labeling, INDs, NDAs, ANDAs, EUAs, Type A, B, C, and D meetings, annual reports, pediatric study plans, orphan drug designations, Fast Track and Breakthrough therapy designations, and others, in addition to leading meetings with regulatory agencies. She has extensive experience in leading multidisciplinary teams to support drug development programs. Dr. Gatza has worked across multiple therapeutic areas including oncology, cardiovascular disease, gastroenterology, metabolic diseases, neurology, dermatology, reproductive health, and infectious diseases, including rare diseases. Dr. Gatza has participated in over 45 FDA meetings and been involved in submissions across 13 FDA Divisions, as well as the Office of Generic Drugs and the Office of Orphan Product Development. Dr. Gatza has a PhD in Cell and Molecular Biology from Baylor College of Medicine and completed a postdoctoral fellowship in breast and colon cancer at Duke University Medical Center.
Learn moreFAQs
Find answers to common questions about our 505(b)(2) CRO expertise.
The 505(b)(2) pathway is an FDA New Drug Application pathway that allows a sponsor to rely on existing data, published literature, or FDA findings for an approved product to reduce the size or scope of a development program for a modified, repurposed, reformulated, or otherwise differentiated product.
The 505(b)(2) pathway may be appropriate when a proposed product differs from an approved drug but can still rely at least in part on existing safety or efficacy data. Common examples include new dosage forms, routes of administration, strengths, formulations, indications, fixed-dose combinations, drug-device combinations, Rx-to-OTC switches, and products supported by bioavailability or bioequivalence bridging. Whether the pathway is suitable depends on the proposed product, the available reference product and literature, the remaining data gaps, and FDA expectations.
A well-designed 505(b)(2) strategy may allow sponsors to rely on existing safety, efficacy, or published data instead of repeating studies unnecessarily. The degree of efficiency depends on the product, indication, reference product, standard of existing data or literature, and FDA expectations.
Common risks include selecting the wrong reference product, not taking full advantage of the pre-IND meeting, failing to justify reliance on existing evidence, misaligning CMC timing with accelerated development, or conducting more studies than necessary. Early, integrated regulatory and development planning can help reduce these risks.
Premier Research supports sponsors by building integrated, approval-focused 505(b)(2) development strategies that reduce unnecessary studies, accelerate timelines, and prepare programs for FDA review. Our teams help determine whether the pathway is appropriate, identify reference products, define data-reliance and bridging strategies, design clinical pharmacology and PK approaches, assess where existing data may support reduced nonclinical requirements, and align CMC planning with accelerated development timelines.
Premier Research helps sponsors prepare for FDA interactions by developing meeting strategies, briefing packages, questions, data reliance arguments, and development rationales. Our teams conduct pre-IND, Type A, Type C, Type D, end-of-phase, and pre-NDA meetings on behalf of sponsors.
The most effective bridging strategies are prepared early and used to support clinical, nonclinical, and regulatory planning. This early strategic evaluation provides the greatest opportunity to reduce development burden, combine studies, and avoid unnecessary studies. However, many sponsors neglect bridging until later in development when it becomes urgent. With appropriate strategy and clinical pharmacology input, it is possible to create an effective bridging strategy later in development. Sometimes an extra study may be needed, or it may be possible to use modeling and/or extrapolation approaches to avoid another study. A gap assessment can help determine the best bridging strategy at the current developmental stage.
The need for nonclinical studies depends on the nature of the asset and how it differs from the reference product. Some 505(b)(2) programs can rely heavily on existing nonclinical and clinical data, while others require targeted nonclinical toxicology or pharmacology studies to address data gaps. Factors such as formulation changes, route of administration, dosing differences, or new excipients may affect the nonclinical requirements. A product-specific assessment is the best way to determine what studies, if any, will be needed.
Sponsors may request additional meetings with FDA when new information emerges, significant questions remain, or the development strategy evolves. A follow-up meeting can be especially valuable if the program direction or strategy changes and additional FDA feedback is needed to advance the program. While typically only one pre-IND meeting is granted, extra feedback can be obtained through a Type C or D meeting.
While we often work with partners to prepare and implement the complete strategy, Premier can conduct an independent strategic review of materials developed by a sponsor. Our regulatory experts assess the proposed strategy and development program for potential gaps or risks and provide recommendations to strengthen the overall strategy before FDA interactions. Or we can just review meeting documents prepared by the sponsor. We can support as much or as little of the process as needed.